By Exec Edge Editorial Staff
Ascentage Pharma said China’s Center for Drug Evaluation has cleared its investigational new drug application for APG-3288, a next-generation Bruton’s tyrosine kinase (BTK) protein degrader, paving the way for clinical testing in the country and advancing the company’s global development strategy.
The company plans to begin a Phase I study in patients with relapsed or refractory hematologic malignancies to assess safety, tolerability and early signs of efficacy.
BTK is a key driver in B-cell cancers such as lymphoma and chronic lymphocytic leukemia, where resistance to existing inhibitors remains a persistent challenge.
READ MORE
IPO Edge Nasdaq Firesides Scheduled for Feb 2, March 19 & May 19
Never Miss our Weekly Highlights HERE
